Gordian launches with $60m and platform that predicts outcomes in age-related diseases

High-throughput in vivo screening platform can test hundreds of gene therapies simultaneously in animals closely mirroring human biology.

Gordian Biotechnology launched today, with $60 million in venture capital and a groundbreaking platform aimed at revolutionizing the discovery of gene therapies for age-related diseases. The San Francisco-based company specializes in in vivo drug discovery and development and claims its approach to screening potential treatments provides unprecedented accuracy and efficiency.

Central to Gordian’s platform is its use of “patient avatars,” animal models that closely mirror human biology, including horses for osteoarthritis (OA) and monkeys for metabolic-associated steatohepatitis (MASH). By testing hundreds of gene therapies simultaneously in individual animals, the company says it can rapidly generate vast amounts of in vivo data, allowing for the identification of the most promising treatments at an early stage.

The company’s proprietary “mosaic screening” technique involves introducing a pooled library of gene therapies into a single sick animal, where different cells receive different treatments. Combined with Gordian’s AI-powered Pythia analysis methodology, this enables the precise measurement of each therapy’s effectiveness in vivo.

In proof-of-concept experiments, Gordian says its platform demonstrated remarkable predictive accuracy, with screen results matching preclinical and clinical outcomes for age-related indications with 80% accuracy. Furthermore, the company says the platform has successfully recapitulated clinical outcomes for targets where clinical data exists, underscoring its potential to streamline drug discovery and development processes.

“Gordian leverages recent advancements in single-cell sequencing and gene therapy to discover and predict what drugs will be successful in a way that would have been inconceivable just five years ago,” said Francisco LePort, CEO of Gordian. “Our ultimate goal is to help people wake up every day, more capable than the one before.”

Gordian’s current focus indications include not only OA and MASH, but also heart failure with preserved ejection fraction and pulmonary fibrosis, and the company claims the platform is suited to a wide range of complex diseases associated with aging.

“Our most severe unmet medical needs are the result of aging. This is due to the complexities of the aging body, often involving multiple comorbidities at once, making research and development especially challenging and expensive,” said Martin Borch Jensen, CSO of Gordian. “Gordian is creating a future in which age-related ailments are treated and cured as effectively as infectious diseases today.”

The company says it has raised $60 million to date from investors including The Longevity Fund, Arctica Ventures, Athos Service GmbH, Gigafund, Founders Fund, Fifty Years, and former Novartis CEO Thomas Ebeling.

“Age-related diseases are incredibly complex, and a living animal, ideally one that is aged and acquired the disease naturally, is the only experimental system that can capture this complexity,” said The Longevity Fund’s Laura Deming. “Our ability to understand these diseases is bottlenecked by the rate we can run tests in these living systems. Scaling that rate by over 100 fold is really exciting and is a huge leap toward curing age-related disease.”